[
    [
        {
            "time": "2018-12-03",
            "original_text": "Cramer Remix: These recession-proof stocks are worth buying on a pullback",
            "features": {
                "keywords": [
                    "recession-proof",
                    "stocks",
                    "pullback"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "Health Care Sector Update for 12/03/2018: ARGX,GBT,GSK,TSRO,AGIO",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "ARGX",
                    "GBT",
                    "GSK",
                    "TSRO",
                    "AGIO"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health care"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "Health Care Sector Update for 12/03/2018: TSRO, GSK, VNDA, GBT, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "Health Care",
                    "Sector Update",
                    "TSRO",
                    "GSK",
                    "VNDA",
                    "GBT",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK",
                    "AMGN"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health care"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "Dutch firm argenx, J&J affiliate to collaborate on cancer therapy",
            "features": {
                "keywords": [
                    "Dutch firm",
                    "argenx",
                    "J&J",
                    "cancer therapy",
                    "collaborate"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health care"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "J&J to Build Blood-Cancer Push With Controversial China Biotech",
            "features": {
                "keywords": [
                    "J&J",
                    "Blood-Cancer",
                    "Controversial",
                    "China Biotech"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health care"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]